The market value of BRC-20 is approximately 2.18 billion US dollars, with a 30.7% increase within the last 24 hours

Bark named CFO Anya Hamill as principal accounting officer effective Oct. 9, 2026. Principal accounting officer Brian Dostie resigned effective Oct. 23, 2026. He stopped serving in the role on Oct. 9. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bark Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-065536), on October 09, 2026, and is solely responsible for the information contained therein.

Microsoft has launched a dedicated AI model, Microsoft-Decision-1, designed specifically for structured decision-making tasks. This model can select the optimal solution from preset options and assign probability scores, supporting scenarios such as routing distribution, content classification, and task prioritization. Internal testing shows that its speed is 35 times faster than GPT-6 Sol, with an input cost of only $0.042 per million tokens and free output.

On October 9, Moderna (MRNA.O) shares rose by about 12% to $220 on Friday, after reaching their highest point since January 2022, as the company was added to the Nasdaq 100 Index (.NDX). Bank of America raised its price target for the stock from $170 to $200. On Thursday, the stock closed at $197. Bank of America analysts maintained a neutral rating and noted that the price target was raised due to a slight reduction in expectations for U.S. COVID-related revenues, offset by anticipated growth in influenza sales by 2027. This also factored in an increase in the expected price for intismeran, as well as projected sales growth for the drug in the coming years; intismeran is a cancer vaccine co-developed with Merck (MRK.N). However, they pointed out that much of intismeran's value has already been reflected in the share price ahead of the European Society for Medical Oncology (ESMO) conference and upcoming data releases. Since the third-quarter earnings report will only be announced after the presentation at the ESMO conference on October 24, Bank of America noted that the significance of the Q3 results is relatively low. Nevertheless, BofA still expects the company to achieve its guidance of up to 10% revenue growth for 2026, with year-end cash holdings reaching $4.7 billion to $5.2 billion. The bank also stated its forecast for third-quarter preventive vaccine revenue is $812 million, below market consensus, and its total revenue estimate of $848 million is likewise below consensus. Since August 18, Moderna's stock price has been on a strong uptrend, following encouraging late-stage clinical data on intismeran, which encouraged investors to buy the stock. Moderna was included in the Nasdaq 100 Index (link), replacing Warner Bros. Discovery, which is set to merge with Paramount Global. Year-to-date, Moderna shares are up about 650%, marking the largest annual gain in its history, making it the top performer in the S&P 500 Index (.SPX) year-to-date. In contrast, the S&P 500 Healthcare Index (.SPXHC) is up only 10.3% so far in 2026. (For the convenience of non-English speakers, Reuters provides automated translation of its reports into several other languages. As automated translation may contain errors or lack required context, Reuters does not guarantee the accuracy of automated translated texts, and these are provided solely for the reader's convenience. Reuters assumes no responsibility for any damage or losses caused by the use of automated translation functionality.)